Ignite Creation Date:
2024-05-06 @ 7:23 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05996484
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-21
First Post:
2023-08-10
Brief Title:
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Sponsor:
Nanfang Hospital Southern Medical University
Organization:
Nanfang Hospital Southern Medical University
Study Overview
Official Title:
Anlotinib in Combination With Toripalimab and Chemotherapy for Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma a Phase II Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib Toripalimab and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell carcinoma The study aims to improve the pathological complete response rate pCR R0 resection rate and disease-free survival DFS in patients undergoing esophageal cancer surgery The findings of this study will provide guidance and new options for the treatment of locally advanced esophageal cancer patients
Detailed Description:
Both anti-angiogenic therapy and immune checkpoint inhibitors have shown preliminary efficacy and safety data in the field of neoadjuvant therapy for esophageal cancer However there is currently no available data on the combination of immune checkpoint inhibitors anti-angiogenic therapy and chemotherapy in neoadjuvant therapy for esophageal cancer Based on the favorable survival benefits of this combination in first-line and second-line treatments for multiple tumors we aim to explore another neoadjuvant treatment approach - adding anti-angiogenic agents to immune checkpoint inhibitor-based neoadjuvant therapy providing a new perioperative treatment strategy for esophageal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None